TAK-233

TAK-233 is a novel, selective small molecule agonist of the 5-hydroxytryptamine type 2C (5-HT2C) receptor. It was developed for the potential treatment of stress urinary incontinence. Preclinical studies demonstrated that TAK-233 enhances urethral resistance and momentary urethra-closing functions via stimulation of the 5-HT2C receptor in both rats and humans. The drug increases sensitivity to transcranial magnetic stimulation-induced urethral contractile responses, indicating its mechanism also operates in humans. Initially developed by Takeda, global rights were later licensed to Outpost Medicine for further development and commercialization[1][2][3][4][5][6][7][9].